The Accuracy of Modified TTMB in the Spatial Distribution of Prostate Cancer

The Study on the Spatial Distribution of Prostate Cancer by Modified Trans-perineal Template-guided Mapping Biopsy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03418207

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

2019-12-31

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

TPS system, trans-perineal template-guided mapping biopsy, prostate cancer, spatial distribution, large tissue slice

Brief summary

Investigators plan to use modified TTMB technology to puncture prostate of participants suspected prostate cancer, especially those with the first negative biopsy , but having a rising PSA.Then, Investigators will simulate the spatial distribution of prostate cancer in patients with positive biopsy before radical prostatectomy by way of the TPS software system . And after the radical prostatectomy ,Investigators will simulate the spatial distribution with the help of large tissue slice technique to compare with preoperative simulation ,which to verify the two simulations are consistent.

Detailed description

Investigators mainly plan to determine the accuracy of the modified TTMB technology in combination with the TPS system on the location of the tumor space distribution by comparing the two simulation, which is significant for the accurate focal thearpy.

Interventions

PROCEDUREtrans-perineal template-guided mapping biopsy

new super saturation of prostate biopsy technique

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

1.Male patients; 2.18 yrs and older, and 90 yrs and younger; 3.Rectal examination reveal prostate nodules; 4.B ultrasound, CT or MRI find abnormal images; 5.PSA\>4ng/ml, abnormal f/t ratio and PSAD

Exclusion criteria

1. Abnormal coagulation function; 2. Severe urinary tract infection; 3. Serious cardiovascular and cerebrovascular disease

Design outcomes

Primary

Measure	Time frame	Description
the spatial distribution based on the biopsy tissue	2 years	to simulate the spatial distribution of cancer based on the biopsy tissue contained cancer with the help of TPS system

Secondary

Measure	Time frame	Description
the spatial distribution based on the large tissue slice technique	2 years	to simulate the spatial distribution based on the large tissue slice technique after radical prostatectomy

Countries

China

Contacts

Primary ContactXuefei Ding, MD

xuefeid@126.com18051061234

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026